Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma

OBJECTIVE: Oesophageal squamous cell carcinoma (OSCC), like other squamous carcinomas, harbour highly recurrent cell cycle pathway alterations, especially hyperactivation of the CCND1/CDK4/6 axis, raising the potential for use of existing CDK4/6 inhibitors in these cancers. Although CDK4/6 inhibitio...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jin, Wu, Zhong, Zhang, Zhouwei, Goss, Louisa, McFarland, James, Nagaraja, Ankur, Xie, Yingtian, Gu, Shengqing, Peng, Ke, Zeng, Yong, Zhang, Xiaoyang, Long, Henry, Nakagawa, Hiroshi, Rustgi, Anil, Diehl, J Alan, Meyerson, Matthew, Wong, Kwok-Kin, Bass, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oesophagus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921580/
https://www.ncbi.nlm.nih.gov/pubmed/33789967
http://dx.doi.org/10.1136/gutjnl-2020-323276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921580/
https://www.ncbi.nlm.nih.gov/pubmed/33789967
http://dx.doi.org/10.1136/gutjnl-2020-323276

Ejemplares similares